Wall Street Analysts Predict a 60.24% Surge for Adma Biologics (ADMA): Important Insights Before You Invest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: NASDAQ.COM
Stock Performance: Adma Biologics (ADMA) shares have risen 23.3% recently, closing at $19.14, with Wall Street analysts projecting a mean price target of $30.67, suggesting a potential upside of 60.2%.
Analyst Price Targets: While the consensus price target shows strong agreement among analysts, there are concerns about the reliability of these targets, as they may be influenced by business relationships and could mislead investors.
Earnings Estimates: Analysts have revised ADMA's earnings estimates upward, indicating optimism about the company's performance, which historically correlates with positive stock price movements.
Investment Caution: Investors are advised to approach price targets with skepticism and consider them as one of many factors in their investment decisions, rather than relying solely on them for potential returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.010
Low
30.00
Averages
30.00
High
30.00
Current: 17.010
Low
30.00
Averages
30.00
High
30.00
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics CEO to Present at J.P. Morgan Healthcare Conference
- Conference Participation: ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM PT, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor interest.
- Product Portfolio: ADMA currently markets three FDA-approved plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, highlighting the company's market positioning and expertise in niche medical areas.
- R&D Initiatives: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, indicating the company's ongoing commitment to innovative drug development aimed at meeting the needs of specific patient populations.
- Manufacturing Capabilities: ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, ensuring the quality and stability of its biologics supply, thereby reinforcing its competitive advantage in the biopharmaceutical market.
Continue Reading
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Continue Reading